[go: up one dir, main page]

WO2002055688A2 - Inhibiteurs de l'histone deacetylase dans le diagnostique et le traitement de neoplasmes de la thyroide - Google Patents

Inhibiteurs de l'histone deacetylase dans le diagnostique et le traitement de neoplasmes de la thyroide Download PDF

Info

Publication number
WO2002055688A2
WO2002055688A2 PCT/US2002/000714 US0200714W WO02055688A2 WO 2002055688 A2 WO2002055688 A2 WO 2002055688A2 US 0200714 W US0200714 W US 0200714W WO 02055688 A2 WO02055688 A2 WO 02055688A2
Authority
WO
WIPO (PCT)
Prior art keywords
thyroid
histone deacetylase
cell
agent
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/000714
Other languages
English (en)
Other versions
WO2002055688A3 (fr
WO2002055688A8 (fr
Inventor
Antonio Tito Fojo
Susan Elaine Bates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to EP02718823A priority Critical patent/EP1356053A2/fr
Priority to JP2002556736A priority patent/JP2005507231A/ja
Priority to AU2002249938A priority patent/AU2002249938B2/en
Priority to US10/250,320 priority patent/US20040132643A1/en
Priority to CA002434269A priority patent/CA2434269A1/fr
Publication of WO2002055688A2 publication Critical patent/WO2002055688A2/fr
Publication of WO2002055688A3 publication Critical patent/WO2002055688A3/fr
Publication of WO2002055688A8 publication Critical patent/WO2002055688A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01048—Histone acetyltransferase (2.3.1.48)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne de nouvelles approches du traitement du cancer de la thyroïde. Ces approches comprennent des méthodes visant à améliorer l'expression génique spécifique à la thyroïde, par exemple des méthodes visant à améliorer l'expression de thyroglobuline et/ou du symporteur de Na<+>/I<-> dans les cellules cancéreuses thyroïdiennes. L'expression améliorée de gènes spécifiques à la thyroïde favorise la différenciation cellulaire et réduit les comportements biologiquement agressifs, tels que l'invasion et la métastase. L'expression améliorée de thyroglobuline et/ou du symporteur de Na<+>/I<-> augmente l'abilité des cellules cancéreuses thyroïdiennes de concentrer l'iode ou l'iodure, ce qui rend les cellules plus sensibles à la thérapie à l'iode radioactive. L'invention concerne également des procédés de détection des néoplasmes de la thyroïde chez un sujet, par l'administration d'une quantité thérapeutiquement efficace d'un inhibiteur de l'histone déacétylase, l'administration d'un agent détectable dont l'absorption ou la concentration dans les cellules thyroïdiennes est augmentée par l'administration de l'inhibiteur de l'histone déacétylase, et la détection de l'agent détectable.
PCT/US2002/000714 2001-01-10 2002-01-09 Inhibiteurs de l'histone deacetylase dans le diagnostique et le traitement de neoplasmes de la thyroide Ceased WO2002055688A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02718823A EP1356053A2 (fr) 2001-01-10 2002-01-09 Inhibiteurs de l'histone deacetylase dans le diagnostique et le traitement de neoplasmes de la thyroide
JP2002556736A JP2005507231A (ja) 2001-01-10 2002-01-09 甲状腺新生物の診断および治療におけるヒストン脱アセチル酵素阻害剤
AU2002249938A AU2002249938B2 (en) 2001-01-10 2002-01-09 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
US10/250,320 US20040132643A1 (en) 2002-01-09 2002-01-09 Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
CA002434269A CA2434269A1 (fr) 2001-01-10 2002-01-09 Inhibiteurs de l'histone deacetylase dans le diagnostique et le traitement de neoplasmes de la thyroide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26073301P 2001-01-10 2001-01-10
US60/260,733 2001-01-10

Publications (3)

Publication Number Publication Date
WO2002055688A2 true WO2002055688A2 (fr) 2002-07-18
WO2002055688A3 WO2002055688A3 (fr) 2003-04-10
WO2002055688A8 WO2002055688A8 (fr) 2003-09-25

Family

ID=22990378

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000714 Ceased WO2002055688A2 (fr) 2001-01-10 2002-01-09 Inhibiteurs de l'histone deacetylase dans le diagnostique et le traitement de neoplasmes de la thyroide

Country Status (5)

Country Link
EP (1) EP1356053A2 (fr)
JP (1) JP2005507231A (fr)
AU (1) AU2002249938B2 (fr)
CA (1) CA2434269A1 (fr)
WO (1) WO2002055688A2 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003107001A1 (fr) * 2002-06-18 2003-12-24 Ulrich Loos Methode de diagnostic et de traitement de metastases et de carcinomes exprimant nis
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007100795A3 (fr) * 2006-02-27 2008-12-18 Gilead Colorado Inc Combinaisons thérapeutiques et méthodes pour amélioration cardio-vasculaire et traitement de maladie cardio-vasculaire
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7683185B2 (en) 2002-11-18 2010-03-23 Queen Mary & Westfield College Histone deacetylase inhibitors
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8110577B2 (en) 2006-10-19 2012-02-07 Queen Mary & Westfield College Histone deacetylase inhibitors
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US8980825B2 (en) 2010-07-12 2015-03-17 Celgene Corporation Romidepsin solid forms and uses thereof
US9101579B2 (en) 2012-11-14 2015-08-11 Celgene Corporation Inhibition of drug resistant cancer cells
US9134325B2 (en) 2012-09-07 2015-09-15 Celgene Corporation Resistance biomarkers for HDAC inhibitors
US9463215B2 (en) 2013-12-27 2016-10-11 Celgene Corporation Romidepsin formulations and uses thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP2049139A4 (fr) 2006-04-24 2009-06-24 Gloucester Pharmaceuticals Inc Traitement de tumeurs exprimant ras

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1173562A2 (fr) * 1999-05-03 2002-01-23 Methylgene, Inc. Inhibition d'histone deacetylase

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003107001A1 (fr) * 2002-06-18 2003-12-24 Ulrich Loos Methode de diagnostic et de traitement de metastases et de carcinomes exprimant nis
US7399884B2 (en) 2002-10-08 2008-07-15 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7683185B2 (en) 2002-11-18 2010-03-23 Queen Mary & Westfield College Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7741494B2 (en) 2005-07-14 2010-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007100795A3 (fr) * 2006-02-27 2008-12-18 Gilead Colorado Inc Combinaisons thérapeutiques et méthodes pour amélioration cardio-vasculaire et traitement de maladie cardio-vasculaire
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US8110577B2 (en) 2006-10-19 2012-02-07 Queen Mary & Westfield College Histone deacetylase inhibitors
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
US8980825B2 (en) 2010-07-12 2015-03-17 Celgene Corporation Romidepsin solid forms and uses thereof
US9518094B2 (en) 2010-07-12 2016-12-13 Celgene Corporation Romidepsin solid forms and uses thereof
US9624271B2 (en) 2010-07-12 2017-04-18 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US9134325B2 (en) 2012-09-07 2015-09-15 Celgene Corporation Resistance biomarkers for HDAC inhibitors
US9101579B2 (en) 2012-11-14 2015-08-11 Celgene Corporation Inhibition of drug resistant cancer cells
US9463215B2 (en) 2013-12-27 2016-10-11 Celgene Corporation Romidepsin formulations and uses thereof
US9468664B2 (en) 2013-12-27 2016-10-18 Celgene Corporation Romidepsin formulations and uses thereof
US9782451B2 (en) 2013-12-27 2017-10-10 Celgene Corporation Romidepsin formulations and uses thereof
US9795650B2 (en) 2013-12-27 2017-10-24 Celgene Corporation Romidepsin formulations and uses thereof

Also Published As

Publication number Publication date
EP1356053A2 (fr) 2003-10-29
CA2434269A1 (fr) 2002-07-18
WO2002055688A3 (fr) 2003-04-10
JP2005507231A (ja) 2005-03-17
AU2002249938B2 (en) 2006-12-21
WO2002055688A8 (fr) 2003-09-25

Similar Documents

Publication Publication Date Title
AU2002249938B2 (en) Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
AU2002249938A1 (en) Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
Kopp et al. Werner & Ingbar’s the Thyroid: A Fundamental and Clinical Text
US20040132643A1 (en) Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
Dadachova et al. The Na+/I− symporter (NIS): imaging and therapeutic applications
Portulano et al. The Na+/I− symporter (NIS): mechanism and medical impact
Hingorani et al. The biology of the sodium iodide symporter and its potential for targeted gene delivery
Furuya et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin
Riesco-Eizaguirre et al. A perspective view of sodium iodide symporter research and its clinical implications
Dohán et al. Advances in Na+/I− symporter (NIS) research in the thyroid and beyond
AU2016369612A1 (en) Polynucleotides encoding methylmalonyl-CoA mutase
Carvalho et al. The importance of sodium/iodide symporter (NIS) for thyroid cancer management
CN114364704B (zh) 修饰的piggybac转座酶多肽、编码其的多核苷酸、引入载体、试剂盒、将靶序列整合到细胞基因组中的方法以及生产细胞的方法
Cho A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy
EP1397387A1 (fr) Anticorps specifiques contre cd44v6
Matsumoto et al. Rescue of severe infantile hypophosphatasia mice by AAV-mediated sustained expression of soluble alkaline phosphatase
Chung et al. Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma
Baker et al. The sodium-iodide symporter
WO2000067762A2 (fr) Promedicaments contenant du selenium en tant que therapie du cancer
Presta et al. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene
Min et al. In vitro and in vivo characteristics of a human colon cancer cell line, SNU-C5N, expressing sodium-iodide symporter
Riesco-Eizaguirre et al. Telomerase-driven expression of the sodium iodide symporter (NIS) for in vivo radioiodide treatment of cancer: a new broad-spectrum NIS-mediated antitumor approach
KR20230131178A (ko) 변형된 엔도뉴클레아제를 사용한 유전자 편집
AU2001252415A1 (en) Bacterial carboxypeptidase CPG2 variants and their use in gene directed enzyme prodrug therapy
Welsh et al. Stimulation of growth hormone synthesis by glucose in islets of Langerhans isolated from transgenic mice.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002249938

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2434269

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002556736

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002718823

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 29/2002 UNDER (22) REPLACE "8 JANUARY 2002 (08.01.2002)" BY "9 JANUARY 2002 (09.01.2002)"

WWP Wipo information: published in national office

Ref document number: 2002718823

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10250320

Country of ref document: US